ContraFect Corp. | Mutual Funds
Mutual Funds that own ContraFect Corp.
Federated Kaufmann Fund
5,180,000
6.52%
0
0.17%
06/29/2018
Vanguard Total Stock Market Index Fund
1,477,832
1.86%
43,200
0%
07/31/2018
Federated Kaufmann Small Cap Fund
690,000
0.87%
0
0.1%
06/29/2018
Vanguard Extended Market Index Fund
546,386
0.69%
100
0%
07/31/2018
Fidelity Spartan Extended Market Index Fund
299,050
0.38%
0
0%
07/31/2018
iShares Micro Cap ETF
166,754
0.21%
0
0.03%
09/06/2018
Federated Kaufmann II Fund
130,000
0.16%
0
0.16%
06/29/2018
Vanguard Institutional Total Stock Market Index Fund
91,364
0.12%
2,400
0%
07/31/2018
Vanguard Balanced Index Fund
30,448
0.04%
4,400
0%
07/31/2018
Vanguard Total Stock Market Index Trust
13,286
0.02%
0
0%
07/31/2018
| Address |
28 Wells Avenue
Yonkers New York 10701
United States
|
|
Employees
|
- |
| Website |
http://www.contrafect.com |
| Updated |
07/08/2019 |
| ContraFect Corp. engages in discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases. Its pipeline consists of CF-301, a bacteriophage-derived lysin with potent activity against Staphylococcus aureus bloodstream infections; and CF-404, which composed of three fully human monoclonal antibodies designed to treat all seasonal strains of human influenza. The company was founded by Robert Nowinski on March 5, 2008 and is headquartered in Yonkers, NY. |
